Search For "dcgi"
DCGI issues guidelines for pharma giants manufacturing COVID-19 va
Updated : 1 week, 1 day ago IST
New Delhi [India], September 23 (ANI): The Drugs Controller General of India (DCGI) has issued a new set of guidelines, focusing on safety, immunogenicity and efficacy parameters for pharma giants who are developing COVID-19 vaccines.
Read More
First cost, time-effective CRISPER test for Covid-19 gets nod for
Updated : 1 week, 3 days ago IST
New Delhi [India], September 20 (ANI): The Drugs Controller General of India (DCGI) has given approval to the Tata Group for the launch of India's first Clustered Regularly Interspaced Short Palindromic (CRISPR) Covid-19 test for commercial launch.
Read More
DCGI approves India's first CRISPR Covid-19 test developed by the
Updated : 1 week, 4 days ago IST
New Delhi [India], September 19 (ANI): The Drug Controller General of India (DCGI), on Saturday gave approval for the commercial launch of India's first Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) test, developed by the Tata Group and CSIR-IGIB (Institute of Genomics a
Read More
DCGI gives nod to Serum Institute to restart phase 2,3 trials for
Updated : 2 weeks, 1 day ago IST
New Delhi [India], September 16 (ANI): The Drugs Controller General of India (DCGI) has allowed Serum Institute of India (SII) to restart its phase two and three clinical trials for COVID-19 vaccine after the pharma major submitted the recommendations of the Data Safety Monitoring Board (DSM
Read More
Serum Institute to resume COVID-19 vaccine trials in India after D
Updated : 2 weeks, 4 days ago IST
New Delhi [India], September 12 (ANI): Hours after clinical trials for AstraZeneca and Oxford University coronavirus vaccine resumed on Saturday in the UK, pharma major Serum Institute of India (SII) said it will resume the trials in India once Drugs Controller General of India (DCGI) gives
Read More
DCGI directs Serum Institute to suspend any new recruitment in pha
Updated : 2 weeks, 5 days ago IST
New Delhi [India], September 12 (ANI): The Drugs Controller General of India (DCGI) Dr VG Somani on Friday ordered the pharma giant Serum Institute of India (SII) to suspend any new recruitment in phase 2 and 3 clinical trials for COVID-19 vaccine till further orders.
Read More
Serum Institute says will adhere to DCGI instructions after show c
Updated : 3 weeks ago IST
New Delhi [India], September 9 (ANI): Hours after the Drugs Controller General of India (DCGI) issued a show-cause notice Serum Institute of India (SII) asking for an explanation as to why the ongoing clinical trial of Covishield vaccine candidate has not been suspended till doubts about
Read More
DCGI sends show cause notice to Serum Institute for not pausing t
Updated : 3 weeks ago IST
New Delhi [India], September 9 (ANI): The Drugs Regulator General of India (DCGI) has issued a show-cause notice to pharma giant Serum Institute of India (SII) asking for an explanation as to why the ongoing clinical trial of Covishield vaccine candidate has not been suspended till doubts
Read More
Dr Reddy's launches Redyx (Remdesivir) in India for COVID-19 treat
Updated : 3 weeks ago IST
Hyderabad (Telangana) [India], September 9 (ANI): Dr Reddy's Laboratories on Wednesday announced the launch of Remdesivir under the brand name Redyx for Indian markets.
Read More
Serum Institute initiates phase 2, 3 clinical study on 1,600 volun
Updated : 1 month, 1 week ago IST
New Delhi [India], August 19 (ANI): Indian pharmaceutical giant Serum Institute of India has initiated the phase 2, 3 clinical trials to evaluate the safety and immune response of coronavirus vaccine candidate on healthy Indian adults after the pharma company got approval from Drugs Controll
Read More
COVID-19: Subject Expert Committee seeks DCGI's nod to use hepatit
Updated : 1 month, 1 week ago IST
New Delhi [India], Aug 19 (ANI): The Subject Expert Committee (SEC) at the Central Drugs Standard Control Organisation (CDSCO) has recommended that the country's top drug regulator grant permission for phase 3 clinical trial using Thymosin @-1 injection 1.6 mg on moderate to severe COVID-19
Read More
Lupin launches Favipiravir in India for COVID treatment at Rs 49 p
Updated : 1 month, 3 weeks ago IST
Mumbai (Maharashtra) [India], Aug 5 (ANI): Pharma major Lupin Ltd on Wednesday announced the launch of Favipiravir in India under the brand name Covihalt for treatment of mild to moderate COVID-19.
Read More